ADAG – adagene inc. - ads, each representing 1.25 ordinary shares (US:NASDAQ)
Stock Stats
News
Adagene (NASDAQ:ADAG) was upgraded by analysts at Guggenheim to a "strong-buy" rating.
Adagene (NASDAQ:ADAG) is now covered by analysts at Guggenheim. They set a "buy" rating on the stock.
Adagene (NASDAQ:ADAG) was upgraded by analysts at Lifesci Capital to a "strong-buy" rating.
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology [Yahoo! Finance]
Adagene Announces Licensing Agreement with Third Arc Bio for Development of Two Masked CD3 T Cell Engagers Utilizing SAFEbody® Technology
Form SCHEDULE 13G/A Adagene Inc. Filed by: WuXi PharmaTech Healthcare Fund I L.P.
Form SCHEDULE 13G/A Adagene Inc. Filed by: Panacea Innovation Ltd
Form 6-K Adagene Inc. For: Nov 13
Form F-3 Adagene Inc.
Top News Gainers
Top News Decliners
Live Event: How Top Hedge Funds Use News To Make Money From The Stock Market & How Ordinary People Are Copying Their Strategies
If you could use the news to make money from the stock market, would you? Join us on our live online event where you’ll discover this simple scientific method that has allowed ordinary people get a huge return from the stock market without excessive risk.